Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016

  • ID: 3802762
  • Company Profile
  • 69 pages
  • Global Markets Direct
  • Sorrento Therapeutics Inc
1 of 3
Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016

Summary

‘Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sorrento Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sorrento Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Sorrento Therapeutics, Inc.
- The report provides overview of Sorrento Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Sorrento Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Sorrento Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Sorrento Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sorrento Therapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sorrento Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables

List of Figures

Sorrento Therapeutics, Inc. Snapshot

Sorrento Therapeutics, Inc. Overview

Key Information

Key Facts

Sorrento Therapeutics, Inc. - Research and Development Overview

Key Therapeutic Areas

Sorrento Therapeutics, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Sorrento Therapeutics, Inc. - Pipeline Products Glance

Sorrento Therapeutics, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Sorrento Therapeutics, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Sorrento Therapeutics, Inc. - Drug Profiles

Cellular Immunotherapy to Target CEA for Oncology

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target PD-L1 for Oncology

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target PSMA for Prostate Cancer

Product Description

Mechanism of Action

R&D Progress

BA-0702

Product Description

Mechanism of Action

R&D Progress

CBA-0710

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target c-KIT for Solid Tumors

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target CD123 for Acute Myeloid Leukemia

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target CD33 for Acute Myeloid Leukemia

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target GD3 for Solid Tumors

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target HER-2 for Glioblastoma

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target HER2 for Oncology

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target IL13R Alpha2 for Glioblastoma Multiforme

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target MUC-16 for Ovarian Cancer

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy to Target ROR1 for Solid Tumor

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit CD47 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit Ghrelin for Obesity

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Target EGFR and Inhibit PD-L1 for Oncology

Product Description

Mechanism of Action

R&D Progress

rituximab biosimilar

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit c-Myc for Solid Tumors and Hematological Malignancies

Product Description

Mechanism of Action

R&D Progress

STI-600

Product Description

Mechanism of Action

R&D Progress

STIA-0168

Product Description

Mechanism of Action

R&D Progress

STIA-1011

Product Description

Mechanism of Action

R&D Progress

STIA-1012

Product Description

Mechanism of Action

R&D Progress

STIA-1014

Product Description

Mechanism of Action

R&D Progress

STIA-1015

Product Description

Mechanism of Action

R&D Progress

STIA-1110

Product Description

Mechanism of Action

R&D Progress

STIB-0201

Product Description

Mechanism of Action

R&D Progress

STIC-0205

Product Description

Mechanism of Action

R&D Progress

STID-0602

Product Description

Mechanism of Action

R&D Progress

BC-001

Product Description

Mechanism of Action

R&D Progress

clostridium difficile vaccine

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Clostridium difficile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies for Hepatitis C

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies to Inhibit WISP1 for Idiopathic Pulmonary Fibrosis

Product Description

Mechanism of Action

R&D Progress

STI-001

Product Description

Mechanism of Action

R&D Progress

Sorrento Therapeutics, Inc. - Pipeline Analysis

Sorrento Therapeutics, Inc. - Pipeline Products by Target

Sorrento Therapeutics, Inc. - Pipeline Products by Route of Administration

Sorrento Therapeutics, Inc. - Pipeline Products by Molecule Type

Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action

Sorrento Therapeutics, Inc. - Recent Pipeline Updates

Sorrento Therapeutics, Inc. - Dormant Projects

Sorrento Therapeutics, Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

paclitaxel

Sorrento Therapeutics, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 69List of Tables

Sorrento Therapeutics, Inc., Key Information

Sorrento Therapeutics, Inc., Key Facts

Sorrento Therapeutics, Inc. - Pipeline by Indication, 2016

Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2016

Sorrento Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016

Sorrento Therapeutics, Inc. - Partnered Products in Pipeline, 2016

Sorrento Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2016

Sorrento Therapeutics, Inc. - Phase II, 2016

Sorrento Therapeutics, Inc. - Phase I, 2016

Sorrento Therapeutics, Inc. - Preclinical, 2016

Sorrento Therapeutics, Inc. - Discovery, 2016

Sorrento Therapeutics, Inc. - Pipeline by Target, 2016

Sorrento Therapeutics, Inc. - Pipeline by Route of Administration, 2016

Sorrento Therapeutics, Inc. - Pipeline by Molecule Type, 2016

Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016

Sorrento Therapeutics, Inc. - Recent Pipeline Updates, 2016

Sorrento Therapeutics, Inc. - Dormant Developmental Projects,2016

Sorrento Therapeutics, Inc. - Discontinued Pipeline Products, 2016

Sorrento Therapeutics, Inc., Subsidiaries 67List of Figures

Sorrento Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016

Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2016

Sorrento Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016

Sorrento Therapeutics, Inc. - Partnered Products in Pipeline, 2016

Sorrento Therapeutics, Inc. - Pipeline by Top 10 Target, 2016

Sorrento Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2016

Sorrento Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll